...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of production economics >Open innovation: A real option to restore value to the biopharmaceutical R&D
【24h】

Open innovation: A real option to restore value to the biopharmaceutical R&D

机译：开放式创新：为生物制药研发创造价值的真正选择

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The pharmaceutical landscape has changed, and new business models, based on alliances, are increasingly being adopted in this industry. Biotechnology advances have pushed this development, and pooling complementary resources coming from incumbents and newcomers is a key skill to succeed: these are the premises for a quick spread of the open innovation (OI) paradigm in this industry. R&D portfolio selection needs R&D project evaluation, and Real Options Analysis (ROA) is acknowledged as a powerful tool to evaluate uncertain projects that have an intrinsic flexibility. The present research aims to foster the use of ROA in the OI field in order to encourage firms to undertake this innovation model; to achieve this goal the authors propose a closed-form model that is easy to implement, to evaluate the OI initiative for selecting an optimal R&D portfolio. The study wants to support managers in optimal R&D portfolio construction in terms of choosing the most promising products, the means by which the related project has to be undertaken (in an open or closed manner; i.e. licensing-in or not) and the self-financing policy. The proposed model can be easily implemented into a spreadsheet, and the inputs needed to run it are usually requested to evaluate projects using the most used net-present-value-based methods. Moreover, some parameters of the model allow strategic aspects to be considered: for example the nature of the project (coreon-core), the impending project phase, and the risk-sharing opportunity. The results of the developed numerical example show that the selected portfolio is well balanced in terms of development stages, coreon-core therapeutic areas and, licensing-in (an inbound open innovation solution), is preferred in the case of products at their early stages of development.
机译：制药业已经发生了变化，并且基于联盟的新商业模式正越来越多地被该行业采用。生物技术的进步推动了这一发展，而汇集来自老牌公司和新来者的互补资源是成功的关键技能：这些是开放创新（OI）范式在该行业中快速传播的前提。研发项目组合的选择需要进行研发项目评估，而实物期权分析（ROA）被认为是评估具有内在灵活性的不确定项目的强大工具。本研究旨在鼓励在OI领域中使用ROA，以鼓励企业采用这种创新模式。为了实现这一目标，作者提出了一个易于实现的封闭形式的模型，以评估用于选择最佳研发投资组合的OI计划。该研究希望在选择最有前途的产品，必须执行相关项目的方式（以开放或封闭方式；即许可或不许可）以及自我管理的基础上，为经理人提供最佳研发组合的支持。融资政策。提议的模型可以轻松地实现到电子表格中，通常需要使用运行模型所需的输入来使用最常用的基于净现值的方法评估项目。此外，该模型的某些参数允许考虑战略方面：例如项目的性质（核心/非核心），即将到来的项目阶段以及风险分担机会。所得数值示例的结果表明，所选产品组合在开发阶段，核心/非核心治疗领域以及许可（入站开放式创新解决方案）方面均取得了很好的平衡，对于产品本身而言，则是首选发展的早期阶段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号